

Global Bevacizumab Generics Market Growth 2024-2030

https://marketpublishers.com/r/GB60A13AD763EN.html

Date: November 2024

Pages: 118

Price: US\$ 3,660.00 (Single User License)

ID: GB60A13AD763EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Bevacizumab generics refer to versions of the medication that are bioequivalent to the original brand-name drug, Avastin. Bevacizumab is a medication used in the treatment of various cancers and certain eye diseases, which works by inhibiting vascular endothelial growth factor (VEGF), a protein that promotes the growth of new blood vessels.

The global Bevacizumab Generics market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LP Information, Inc. (LPI) 'newest research report, the "Bevacizumab Generics Industry Forecast" looks at past sales and reviews total world Bevacizumab Generics sales in 2023, providing a comprehensive analysis by region and market sector of projected Bevacizumab Generics sales for 2024 through 2030. With Bevacizumab Generics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Bevacizumab Generics industry.

This Insight Report provides a comprehensive analysis of the global Bevacizumab Generics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bevacizumab Generics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Bevacizumab Generics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors



shaping the global outlook for Bevacizumab Generics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bevacizumab Generics.

United States market for Bevacizumab Generics is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Bevacizumab Generics is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Bevacizumab Generics is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Bevacizumab Generics players cover Amneal Pharmaceuticals, Amgen, Celltrion Healthcare, Pfizer, Qilu Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Bevacizumab Generics market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

100mg per Vial

400mg per Vial

Segmentation by Application:

Hospital and Clinic

Retail Pharmacies

Other




This report also splits the market by region:

eport also splits the market by region:		
Americas		
	United States	
	Canada	
	Mexico	
	Brazil	
APAC		
	China	
	Japan	
	Korea	
	Southeast Asia	
	India	
	Australia	
Europe		
	Germany	
	France	
	UK	
	Italy	

Russia







Zhejiang Beta Pharma

Key Questions Addressed in this Report

What is the 10-year outlook for the global Bevacizumab Generics market?

What factors are driving Bevacizumab Generics market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Bevacizumab Generics market opportunities vary by end market size?

How does Bevacizumab Generics break out by Type, by Application?



Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
- 2.1.1 Global Bevacizumab Generics Annual Sales 2019-2030
- 2.1.2 World Current & Future Analysis for Bevacizumab Generics by Geographic Region, 2019, 2023 & 2030
- 2.1.3 World Current & Future Analysis for Bevacizumab Generics by Country/Region, 2019, 2023 & 2030
- 2.2 Bevacizumab Generics Segment by Type
 - 2.2.1 100mg per Vial
 - 2.2.2 400mg per Vial
- 2.3 Bevacizumab Generics Sales by Type
 - 2.3.1 Global Bevacizumab Generics Sales Market Share by Type (2019-2024)
 - 2.3.2 Global Bevacizumab Generics Revenue and Market Share by Type (2019-2024)
 - 2.3.3 Global Bevacizumab Generics Sale Price by Type (2019-2024)
- 2.4 Bevacizumab Generics Segment by Application
 - 2.4.1 Hospital and Clinic
 - 2.4.2 Retail Pharmacies
 - 2.4.3 Other
- 2.5 Bevacizumab Generics Sales by Application
 - 2.5.1 Global Bevacizumab Generics Sale Market Share by Application (2019-2024)
- 2.5.2 Global Bevacizumab Generics Revenue and Market Share by Application (2019-2024)
 - 2.5.3 Global Bevacizumab Generics Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY



- 3.1 Global Bevacizumab Generics Breakdown Data by Company
 - 3.1.1 Global Bevacizumab Generics Annual Sales by Company (2019-2024)
- 3.1.2 Global Bevacizumab Generics Sales Market Share by Company (2019-2024)
- 3.2 Global Bevacizumab Generics Annual Revenue by Company (2019-2024)
 - 3.2.1 Global Bevacizumab Generics Revenue by Company (2019-2024)
- 3.2.2 Global Bevacizumab Generics Revenue Market Share by Company (2019-2024)
- 3.3 Global Bevacizumab Generics Sale Price by Company
- 3.4 Key Manufacturers Bevacizumab Generics Producing Area Distribution, Sales Area, Product Type
 - 3.4.1 Key Manufacturers Bevacizumab Generics Product Location Distribution
 - 3.4.2 Players Bevacizumab Generics Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
- 3.6 New Products and Potential Entrants
- 3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR BEVACIZUMAB GENERICS BY GEOGRAPHIC REGION

- 4.1 World Historic Bevacizumab Generics Market Size by Geographic Region (2019-2024)
 - 4.1.1 Global Bevacizumab Generics Annual Sales by Geographic Region (2019-2024)
- 4.1.2 Global Bevacizumab Generics Annual Revenue by Geographic Region (2019-2024)
- 4.2 World Historic Bevacizumab Generics Market Size by Country/Region (2019-2024)
- 4.2.1 Global Bevacizumab Generics Annual Sales by Country/Region (2019-2024)
- 4.2.2 Global Bevacizumab Generics Annual Revenue by Country/Region (2019-2024)
- 4.3 Americas Bevacizumab Generics Sales Growth
- 4.4 APAC Bevacizumab Generics Sales Growth
- 4.5 Europe Bevacizumab Generics Sales Growth
- 4.6 Middle East & Africa Bevacizumab Generics Sales Growth

5 AMERICAS

- 5.1 Americas Bevacizumab Generics Sales by Country
- 5.1.1 Americas Bevacizumab Generics Sales by Country (2019-2024)
- 5.1.2 Americas Bevacizumab Generics Revenue by Country (2019-2024)



- 5.2 Americas Bevacizumab Generics Sales by Type (2019-2024)
- 5.3 Americas Bevacizumab Generics Sales by Application (2019-2024)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Bevacizumab Generics Sales by Region
 - 6.1.1 APAC Bevacizumab Generics Sales by Region (2019-2024)
- 6.1.2 APAC Bevacizumab Generics Revenue by Region (2019-2024)
- 6.2 APAC Bevacizumab Generics Sales by Type (2019-2024)
- 6.3 APAC Bevacizumab Generics Sales by Application (2019-2024)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Bevacizumab Generics by Country
 - 7.1.1 Europe Bevacizumab Generics Sales by Country (2019-2024)
 - 7.1.2 Europe Bevacizumab Generics Revenue by Country (2019-2024)
- 7.2 Europe Bevacizumab Generics Sales by Type (2019-2024)
- 7.3 Europe Bevacizumab Generics Sales by Application (2019-2024)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Bevacizumab Generics by Country
 - 8.1.1 Middle East & Africa Bevacizumab Generics Sales by Country (2019-2024)



- 8.1.2 Middle East & Africa Bevacizumab Generics Revenue by Country (2019-2024)
- 8.2 Middle East & Africa Bevacizumab Generics Sales by Type (2019-2024)
- 8.3 Middle East & Africa Bevacizumab Generics Sales by Application (2019-2024)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Bevacizumab Generics
- 10.3 Manufacturing Process Analysis of Bevacizumab Generics
- 10.4 Industry Chain Structure of Bevacizumab Generics

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Bevacizumab Generics Distributors
- 11.3 Bevacizumab Generics Customer

12 WORLD FORECAST REVIEW FOR BEVACIZUMAB GENERICS BY GEOGRAPHIC REGION

- 12.1 Global Bevacizumab Generics Market Size Forecast by Region
 - 12.1.1 Global Bevacizumab Generics Forecast by Region (2025-2030)
- 12.1.2 Global Bevacizumab Generics Annual Revenue Forecast by Region (2025-2030)
- 12.2 Americas Forecast by Country (2025-2030)
- 12.3 APAC Forecast by Region (2025-2030)



- 12.4 Europe Forecast by Country (2025-2030)
- 12.5 Middle East & Africa Forecast by Country (2025-2030)
- 12.6 Global Bevacizumab Generics Forecast by Type (2025-2030)
- 12.7 Global Bevacizumab Generics Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

- 13.1 Amneal Pharmaceuticals
 - 13.1.1 Amneal Pharmaceuticals Company Information
- 13.1.2 Amneal Pharmaceuticals Bevacizumab Generics Product Portfolios and Specifications
- 13.1.3 Amneal Pharmaceuticals Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.1.4 Amneal Pharmaceuticals Main Business Overview
 - 13.1.5 Amneal Pharmaceuticals Latest Developments
- 13.2 Amgen
- 13.2.1 Amgen Company Information
- 13.2.2 Amgen Bevacizumab Generics Product Portfolios and Specifications
- 13.2.3 Amgen Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.2.4 Amgen Main Business Overview
 - 13.2.5 Amgen Latest Developments
- 13.3 Celltrion Healthcare
 - 13.3.1 Celltrion Healthcare Company Information
- 13.3.2 Celltrion Healthcare Bevacizumab Generics Product Portfolios and Specifications
- 13.3.3 Celltrion Healthcare Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.3.4 Celltrion Healthcare Main Business Overview
 - 13.3.5 Celltrion Healthcare Latest Developments
- 13.4 Pfizer
 - 13.4.1 Pfizer Company Information
 - 13.4.2 Pfizer Bevacizumab Generics Product Portfolios and Specifications
- 13.4.3 Pfizer Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.4.4 Pfizer Main Business Overview
 - 13.4.5 Pfizer Latest Developments
- 13.5 Qilu Pharma
- 13.5.1 Qilu Pharma Company Information



- 13.5.2 Qilu Pharma Bevacizumab Generics Product Portfolios and Specifications
- 13.5.3 Qilu Pharma Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.5.4 Qilu Pharma Main Business Overview
 - 13.5.5 Qilu Pharma Latest Developments
- 13.6 Chia Tai Tianqing
 - 13.6.1 Chia Tai Tianqing Company Information
 - 13.6.2 Chia Tai Tianqing Bevacizumab Generics Product Portfolios and Specifications
- 13.6.3 Chia Tai Tianqing Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.6.4 Chia Tai Tianqing Main Business Overview
 - 13.6.5 Chia Tai Tianqing Latest Developments
- 13.7 Jiangsu Hengrui Pharmaceuticals
- 13.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 13.7.2 Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Product Portfolios and Specifications
- 13.7.3 Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.7.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
 - 13.7.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
- 13.8 Innovent
 - 13.8.1 Innovent Company Information
 - 13.8.2 Innovent Bevacizumab Generics Product Portfolios and Specifications
- 13.8.3 Innovent Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.8.4 Innovent Main Business Overview
 - 13.8.5 Innovent Latest Developments
- 13.9 Bio-Thera Solutions
 - 13.9.1 Bio-Thera Solutions Company Information
- 13.9.2 Bio-Thera Solutions Bevacizumab Generics Product Portfolios and Specifications
- 13.9.3 Bio-Thera Solutions Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.9.4 Bio-Thera Solutions Main Business Overview
 - 13.9.5 Bio-Thera Solutions Latest Developments
- 13.10 SinoCellTech
- 13.10.1 SinoCellTech Company Information
- 13.10.2 SinoCellTech Bevacizumab Generics Product Portfolios and Specifications
- 13.10.3 SinoCellTech Bevacizumab Generics Sales, Revenue, Price and Gross



Margin (2019-2024)

- 13.10.4 SinoCellTech Main Business Overview
- 13.10.5 SinoCellTech Latest Developments
- 13.11 Shanghai Henlius Biotech
 - 13.11.1 Shanghai Henlius Biotech Company Information
- 13.11.2 Shanghai Henlius Biotech Bevacizumab Generics Product Portfolios and Specifications
- 13.11.3 Shanghai Henlius Biotech Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.11.4 Shanghai Henlius Biotech Main Business Overview
 - 13.11.5 Shanghai Henlius Biotech Latest Developments
- 13.12 Zhejiang Beta Pharma
 - 13.12.1 Zhejiang Beta Pharma Company Information
- 13.12.2 Zhejiang Beta Pharma Bevacizumab Generics Product Portfolios and Specifications
- 13.12.3 Zhejiang Beta Pharma Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.12.4 Zhejiang Beta Pharma Main Business Overview
 - 13.12.5 Zhejiang Beta Pharma Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OFTABLES

- Table 1. Bevacizumab Generics Annual Sales CAGR by Geographic Region (2019,
- 2023 & 2030) & (\$ millions)
- Table 2. Bevacizumab Generics Annual Sales CAGR by Country/Region (2019, 2023 &
- 2030) & (\$ millions)
- Table 3. Major Players of 100mg per Vial
- Table 4. Major Players of 400mg per Vial
- Table 5. Global Bevacizumab Generics Sales by Type (2019-2024) & (K Dose)
- Table 6. Global Bevacizumab Generics Sales Market Share byType (2019-2024)
- Table 7. Global Bevacizumab Generics Revenue by Type (2019-2024) & (\$ million)
- Table 8. Global Bevacizumab Generics Revenue Market Share by Type (2019-2024)
- Table 9. Global Bevacizumab Generics Sale Price byType (2019-2024) & (US\$/Dose)
- Table 10. Global Bevacizumab Generics Sale by Application (2019-2024) & (K Dose)
- Table 11. Global Bevacizumab Generics Sale Market Share by Application (2019-2024)
- Table 12. Global Bevacizumab Generics Revenue by Application (2019-2024) & (\$



million)

- Table 13. Global Bevacizumab Generics Revenue Market Share by Application (2019-2024)
- Table 14. Global Bevacizumab Generics Sale Price by Application (2019-2024) & (US\$/Dose)
- Table 15. Global Bevacizumab Generics Sales by Company (2019-2024) & (K Dose)
- Table 16. Global Bevacizumab Generics Sales Market Share by Company (2019-2024)
- Table 17. Global Bevacizumab Generics Revenue by Company (2019-2024) & (\$ millions)
- Table 18. Global Bevacizumab Generics Revenue Market Share by Company (2019-2024)
- Table 19. Global Bevacizumab Generics Sale Price by Company (2019-2024) & (US\$/Dose)
- Table 20. Key Manufacturers Bevacizumab Generics Producing Area Distribution and Sales Area
- Table 21. Players Bevacizumab Generics Products Offered
- Table 22. Bevacizumab Generics Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
- Table 23. New Products and Potential Entrants
- Table 24. Market M&A Activity & Strategy
- Table 25. Global Bevacizumab Generics Sales by Geographic Region (2019-2024) & (K Dose)
- Table 26. Global Bevacizumab Generics Sales Market Share Geographic Region (2019-2024)
- Table 27. Global Bevacizumab Generics Revenue by Geographic Region (2019-2024) & (\$ millions)
- Table 28. Global Bevacizumab Generics Revenue Market Share by Geographic Region (2019-2024)
- Table 29. Global Bevacizumab Generics Sales by Country/Region (2019-2024) & (K Dose)
- Table 30. Global Bevacizumab Generics Sales Market Share by Country/Region (2019-2024)
- Table 31. Global Bevacizumab Generics Revenue by Country/Region (2019-2024) & (\$ millions)
- Table 32. Global Bevacizumab Generics Revenue Market Share by Country/Region (2019-2024)
- Table 33. Americas Bevacizumab Generics Sales by Country (2019-2024) & (K Dose)
- Table 34. Americas Bevacizumab Generics Sales Market Share by Country (2019-2024)



- Table 35. Americas Bevacizumab Generics Revenue by Country (2019-2024) & (\$ millions)
- Table 36. Americas Bevacizumab Generics Sales byType (2019-2024) & (K Dose)
- Table 37. Americas Bevacizumab Generics Sales by Application (2019-2024) & (K Dose)
- Table 38. APAC Bevacizumab Generics Sales by Region (2019-2024) & (K Dose)
- Table 39. APAC Bevacizumab Generics Sales Market Share by Region (2019-2024)
- Table 40. APAC Bevacizumab Generics Revenue by Region (2019-2024) & (\$ millions)
- Table 41. APAC Bevacizumab Generics Sales byType (2019-2024) & (K Dose)
- Table 42. APAC Bevacizumab Generics Sales by Application (2019-2024) & (K Dose)
- Table 43. Europe Bevacizumab Generics Sales by Country (2019-2024) & (K Dose)
- Table 44. Europe Bevacizumab Generics Revenue by Country (2019-2024) & (\$ millions)
- Table 45. Europe Bevacizumab Generics Sales byType (2019-2024) & (K Dose)
- Table 46. Europe Bevacizumab Generics Sales by Application (2019-2024) & (K Dose)
- Table 47. Middle East & Africa Bevacizumab Generics Sales by Country (2019-2024) & (K Dose)
- Table 48. Middle East & Africa Bevacizumab Generics Revenue Market Share by Country (2019-2024)
- Table 49. Middle East & Africa Bevacizumab Generics Sales byType (2019-2024) & (K Dose)
- Table 50. Middle East & Africa Bevacizumab Generics Sales by Application (2019-2024) & (K Dose)
- Table 51. Key Market Drivers & Growth Opportunities of Bevacizumab Generics
- Table 52. Key Market Challenges & Risks of Bevacizumab Generics
- Table 53. Key IndustryTrends of Bevacizumab Generics
- Table 54. Bevacizumab Generics Raw Material
- Table 55. Key Suppliers of Raw Materials
- Table 56. Bevacizumab Generics Distributors List
- Table 57. Bevacizumab Generics Customer List
- Table 58. Global Bevacizumab Generics SalesForecast by Region (2025-2030) & (K Dose)
- Table 59. Global Bevacizumab Generics RevenueForecast by Region (2025-2030) & (\$ millions)
- Table 60. Americas Bevacizumab Generics SalesForecast by Country (2025-2030) & (K Dose)
- Table 61. Americas Bevacizumab Generics Annual RevenueForecast by Country (2025-2030) & (\$ millions)
- Table 62. APAC Bevacizumab Generics SalesForecast by Region (2025-2030) & (K



Dose)

Table 63. APAC Bevacizumab Generics Annual RevenueForecast by Region (2025-2030) & (\$ millions)

Table 64. Europe Bevacizumab Generics SalesForecast by Country (2025-2030) & (K Dose)

Table 65. Europe Bevacizumab Generics RevenueForecast by Country (2025-2030) & (\$ millions)

Table 66. Middle East & Africa Bevacizumab Generics SalesForecast by Country (2025-2030) & (K Dose)

Table 67. Middle East & Africa Bevacizumab Generics RevenueForecast by Country (2025-2030) & (\$ millions)

Table 68. Global Bevacizumab Generics SalesForecast byType (2025-2030) & (K Dose)

Table 69. Global Bevacizumab Generics RevenueForecast byType (2025-2030) & (\$ millions)

Table 70. Global Bevacizumab Generics SalesForecast by Application (2025-2030) & (K Dose)

Table 71. Global Bevacizumab Generics RevenueForecast by Application (2025-2030) & (\$ millions)

Table 72. Amneal Pharmaceuticals Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors

Table 73. Amneal Pharmaceuticals Bevacizumab Generics Product Portfolios and Specifications

Table 74. Amneal Pharmaceuticals Bevacizumab Generics Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 75. Amneal Pharmaceuticals Main Business

Table 76. Amneal Pharmaceuticals Latest Developments

Table 77. Amgen Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors

Table 78. Amgen Bevacizumab Generics Product Portfolios and Specifications

Table 79. Amgen Bevacizumab Generics Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 80. Amgen Main Business

Table 81. Amgen Latest Developments

Table 82. Celltrion Healthcare Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors

Table 83. Celltrion Healthcare Bevacizumab Generics Product Portfolios and Specifications

Table 84. Celltrion Healthcare Bevacizumab Generics Sales (K Dose), Revenue (\$



Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 85. Celltrion Healthcare Main Business

Table 86. Celltrion Healthcare Latest Developments

Table 87. Pfizer Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors

Table 88. Pfizer Bevacizumab Generics Product Portfolios and Specifications

Table 89. Pfizer Bevacizumab Generics Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 90. Pfizer Main Business

Table 91. Pfizer Latest Developments

Table 92. Qilu Pharma Basic Information, Bevacizumab Generics Manufacturing Base,

Sales Area and Its Competitors

Table 93. Qilu Pharma Bevacizumab Generics Product Portfolios and Specifications

Table 94. Qilu Pharma Bevacizumab Generics Sales (K Dose), Revenue (\$ Million),

Price (US\$/Dose) and Gross Margin (2019-2024)

Table 95. Qilu Pharma Main Business

Table 96. Qilu Pharma Latest Developments

Table 97. ChiaTaiTianqing Basic Information, Bevacizumab Generics Manufacturing

Base, Sales Area and Its Competitors

Table 98. ChiaTaiTianqing Bevacizumab Generics Product Portfolios and Specifications

Table 99. ChiaTaiTianqing Bevacizumab Generics Sales (K Dose), Revenue (\$ Million),

Price (US\$/Dose) and Gross Margin (2019-2024)

Table 100. ChiaTaiTianging Main Business

Table 101. ChiaTaiTianging Latest Developments

Table 102. Jiangsu Hengrui Pharmaceuticals Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors

Table 103. Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Product Portfolios and Specifications

Table 104. Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Sales (K Dose),

Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 105. Jiangsu Hengrui Pharmaceuticals Main Business

Table 106. Jiangsu Hengrui Pharmaceuticals Latest Developments

Table 107. Innovent Basic Information, Bevacizumab Generics Manufacturing Base,

Sales Area and Its Competitors

Table 108. Innovent Bevacizumab Generics Product Portfolios and Specifications

Table 109. Innovent Bevacizumab Generics Sales (K Dose), Revenue (\$ Million), Price

(US\$/Dose) and Gross Margin (2019-2024)

Table 110. Innovent Main Business

Table 111. Innovent Latest Developments



Table 112. Bio-Thera Solutions Basic Information, Bevacizumab Generics

Manufacturing Base, Sales Area and Its Competitors

Table 113. Bio-Thera Solutions Bevacizumab Generics Product Portfolios and Specifications

Table 114. Bio-Thera Solutions Bevacizumab Generics Sales (K Dose), Revenue (\$

Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 115. Bio-Thera Solutions Main Business

Table 116. Bio-Thera Solutions Latest Developments

Table 117. SinoCellTech Basic Information, Bevacizumab Generics Manufacturing

Base, Sales Area and Its Competitors

Table 118. SinoCellTech Bevacizumab Generics Product Portfolios and Specifications

Table 119. SinoCellTech Bevacizumab Generics Sales (K Dose), Revenue (\$ Million),

Price (US\$/Dose) and Gross Margin (2019-2024)

Table 120. SinoCellTech Main Business

Table 121. SinoCellTech Latest Developments

Table 122. Shanghai Henlius Biotech Basic Information, Bevacizumab Generics

Manufacturing Base, Sales Area and Its Competitors

Table 123. Shanghai Henlius Biotech Bevacizumab Generics Product Portfolios and Specifications

Table 124. Shanghai Henlius Biotech Bevacizumab Generics Sales (K Dose), Revenue

(\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 125. Shanghai Henlius Biotech Main Business

Table 126. Shanghai Henlius Biotech Latest Developments

Table 127. Zhejiang Beta Pharma Basic Information, Bevacizumab Generics

Manufacturing Base, Sales Area and Its Competitors

Table 128. Zhejiang Beta Pharma Bevacizumab Generics Product Portfolios and Specifications

Table 129. Zhejiang Beta Pharma Bevacizumab Generics Sales (K Dose), Revenue (\$

Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 130. Zhejiang Beta Pharma Main Business

Table 131. Zhejiang Beta Pharma Latest Developments

LIST OFFIGURES

Figure 1. Picture of Bevacizumab Generics

Figure 2. Bevacizumab Generics Report Years Considered

Figure 3. Research Objectives



- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Bevacizumab Generics Sales Growth Rate 2019-2030 (K Dose)
- Figure 7. Global Bevacizumab Generics Revenue Growth Rate 2019-2030 (\$ millions)
- Figure 8. Bevacizumab Generics Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Figure 9. Bevacizumab Generics Sales Market Share by Country/Region (2023)
- Figure 10. Bevacizumab Generics Sales Market Share by Country/Region (2019, 2023 & 2030)
- Figure 11. Product Picture of 100mg per Vial
- Figure 12. Product Picture of 400mg per Vial
- Figure 13. Global Bevacizumab Generics Sales Market Share by Type in 2023
- Figure 14. Global Bevacizumab Generics Revenue Market Share byType (2019-2024)
- Figure 15. Bevacizumab Generics Consumed in Hospital and Clinic
- Figure 16. Global Bevacizumab Generics Market: Hospital and Clinic (2019-2024) & (K Dose)
- Figure 17. Bevacizumab Generics Consumed in Retail Pharmacies
- Figure 18. Global Bevacizumab Generics Market: Retail Pharmacies (2019-2024) & (K Dose)
- Figure 19. Bevacizumab Generics Consumed in Other
- Figure 20. Global Bevacizumab Generics Market: Other (2019-2024) & (K Dose)
- Figure 21. Global Bevacizumab Generics Sale Market Share by Application (2023)
- Figure 22. Global Bevacizumab Generics Revenue Market Share by Application in 2023
- Figure 23. Bevacizumab Generics Sales by Company in 2023 (K Dose)
- Figure 24. Global Bevacizumab Generics Sales Market Share by Company in 2023
- Figure 25. Bevacizumab Generics Revenue by Company in 2023 (\$ millions)
- Figure 26. Global Bevacizumab Generics Revenue Market Share by Company in 2023
- Figure 27. Global Bevacizumab Generics Sales Market Share by Geographic Region (2019-2024)
- Figure 28. Global Bevacizumab Generics Revenue Market Share by Geographic Region in 2023
- Figure 29. Americas Bevacizumab Generics Sales 2019-2024 (K Dose)
- Figure 30. Americas Bevacizumab Generics Revenue 2019-2024 (\$ millions)
- Figure 31. APAC Bevacizumab Generics Sales 2019-2024 (K Dose)
- Figure 32. APAC Bevacizumab Generics Revenue 2019-2024 (\$ millions)
- Figure 33. Europe Bevacizumab Generics Sales 2019-2024 (K Dose)
- Figure 34. Europe Bevacizumab Generics Revenue 2019-2024 (\$ millions)
- Figure 35. Middle East & Africa Bevacizumab Generics Sales 2019-2024 (K Dose)
- Figure 36. Middle East & Africa Bevacizumab Generics Revenue 2019-2024 (\$ millions)



- Figure 37. Americas Bevacizumab Generics Sales Market Share by Country in 2023
- Figure 38. Americas Bevacizumab Generics Revenue Market Share by Country (2019-2024)
- Figure 39. Americas Bevacizumab Generics Sales Market Share byType (2019-2024)
- Figure 40. Americas Bevacizumab Generics Sales Market Share by Application (2019-2024)
- Figure 41. United States Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 42. Canada Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 43. Mexico Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 44. Brazil Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 45. APAC Bevacizumab Generics Sales Market Share by Region in 2023
- Figure 46. APAC Bevacizumab Generics Revenue Market Share by Region (2019-2024)
- Figure 47. APAC Bevacizumab Generics Sales Market Share byType (2019-2024)
- Figure 48. APAC Bevacizumab Generics Sales Market Share by Application (2019-2024)
- Figure 49. China Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 50. Japan Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 51. South Korea Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 52. Southeast Asia Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 53. India Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 54. Australia Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 55. ChinaTaiwan Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 56. Europe Bevacizumab Generics Sales Market Share by Country in 2023
- Figure 57. Europe Bevacizumab Generics Revenue Market Share by Country (2019-2024)
- Figure 58. Europe Bevacizumab Generics Sales Market Share byType (2019-2024)
- Figure 59. Europe Bevacizumab Generics Sales Market Share by Application (2019-2024)
- Figure 60. Germany Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 61. France Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 62. UK Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 63. Italy Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 64. Russia Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)
- Figure 65. Middle East & Africa Bevacizumab Generics Sales Market Share by Country (2019-2024)



Figure 66. Middle East & Africa Bevacizumab Generics Sales Market Share byType (2019-2024)

Figure 67. Middle East & Africa Bevacizumab Generics Sales Market Share by Application (2019-2024)

Figure 68. Egypt Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)

Figure 69. South Africa Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)

Figure 70. Israel Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)

Figure 71. Turkey Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)

Figure 72. GCC Countries Bevacizumab Generics Revenue Growth 2019-2024 (\$ millions)

Figure 73. Manufacturing Cost Structure Analysis of Bevacizumab Generics in 2023

Figure 74. Manufacturing Process Analysis of Bevacizumab Generics

Figure 75. Industry Chain Structure of Bevacizumab Generics

Figure 76. Channels of Distribution

Figure 77. Global Bevacizumab Generics Sales MarketForecast by Region (2025-2030)

Figure 78. Global Bevacizumab Generics Revenue Market ShareForecast by Region (2025-2030)

Figure 79. Global Bevacizumab Generics Sales Market ShareForecast byType (2025-2030)

Figure 80. Global Bevacizumab Generics Revenue Market ShareForecast byType (2025-2030)

Figure 81. Global Bevacizumab Generics Sales Market ShareForecast by Application (2025-2030)

Figure 82. Global Bevacizumab Generics Revenue Market ShareForecast by Application (2025-2030)



I would like to order

Product name: Global Bevacizumab Generics Market Growth 2024-2030 Product link: https://marketpublishers.com/r/GB60A13AD763EN.html

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GB60A13AD763EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970